Medical network on December 12 - EvaluatePharma released the latest global industry foresight report in 2017, is worth to pay close attention to the following points:
Low Pfizer (Pfizer) still dominated the pharmaceutical industry, in 2017 the global prescription and OTC sales of nearly $50 billion.
Complaints of wooden sheet (Humira) or the world's best selling drug resistance;
Low Roche (Roche) and Sanofi (Sanofi) eagerly awaiting their key products, including Roche is multiple sclerosis therapy drug Ocrevus, Sanofi is dermatosis treatment dupilumab;
Low Lilly (Eli Lilly) tadalafil (Cialis) and Pfizer (Pfizer) of sildenafil (Viagra) will face the biggest threat to the United States patent;
Low possible tax reform and an influx of money back or for giant m&a plays;
Low cutting-edge technology such as CAR - T therapy, the Crispr gene editing technology and the progress of gene therapy.
The key to look at the world's ten biggest 2017 top ten best-selling drugs and drug companies.
Biological threats like medicine seven big blockbuster drugs
According to the forecast, the 2017 global Top 10 best-selling drug list, there is no "dark horse" appeared. Ada wood sheet resistance to still has topped $17.6 billion in annual sales, for many pharmaceutical companies, have to rely on the whole product line to achieve this huge value. However, AbbVie (AbbVie) "good day" is no longer: Ada wood sheet resistance of biological threats like medicine is approaching, the fastest is expected to market in 2018. Biological medicine like power is more than that, the 2017 global top ten best-selling drug in half a dozen other products will also be threatened by competition.
However, in the list of the 2nd drug lenalidomide (Revlimid) is still strong, it is the new base medicine (its) pillar of growth in recent years, and will continue to maintain. It is predicted that in 2017, its annual sales of $8.1 billion, in a separate report, EvaluatePharma predict the sales will total $13 billion in 2022. Pfizer's pneumonia vaccine pei son (Prevnar 13) are still enjoying the patent protection for a long time, its annual sales in 2017 is expected to be $6 billion. This achievement seems to is black and white, but a very important reason is JiBai gave himself: pei son was quickly covered market, that didn't leave much to fill the blank.
Gilead not sorrow "headlines"
And, of course, is a popular drug that must be in patents expire before to meet sales fell sharply. In cooling hepatitis c drug market, Gilead (Gilead Sciences) Harvoni unfortunately become a part of it. It is predicted that in 2017 annual sales of the drug from the nearly hundred million dollar fell to $7 billion this year. Geely's entire hepatitis c drug product portfolio, including for all genotypes of HCV drugs Epclusa, expected can only lead to $11.7 billion in sales.
EvaluatePharma described this as "the collapse of the dynasty. This year, geely's entire hepatitis c drug product portfolio is expected to contribute $14.9 billion, compared to the new medicine more than $11.2 billion in annual revenue goal. Currently, gilead is in fill sales loss under the great pressure, investors are satisfied with the current situation is not. Perhaps, gilead to save their income measures will make the headlines in 2017.
Outside calls big mergers and acquisitions of gilead is particularly high. In fact, the cash in hand, overseas assets have more than $16 billion, if the government implement tax policies, trump is expected to return the money, the United States. However, once all pharmaceutical companies in the U.S. under the condition of the minimal cost to offshore cash to take home, perhaps also will push the price rising sharply.
Looking back again similar drug threat. Thanks lilly with Boehringer Ingelheim (Boehringer represent Ingelheim) of similar biological medicine (plan this month in the United States listed), sanofi (Lantus) when come directly fell to 2017 of the world's Top 10 best-selling drug bottom, prediction of annual sales in 2016 from $6.9 billion to $2017 in 5.2 billion. Infliximab (Remicade, in addition, Pfizer approval sheet (Remicade) biological similar drug resistance, will also be Johnson & Johnson (Johnson & Johnson) on the drug, is expected to receive $5.9 billion in sales at risk.
Meanwhile, owned the mountain's (Sandoz) in accordance with the heap (Enbrel) biological medicine has received FDA approval, similar but Amgen (Amgen) still delay resistance its listed by patent court. In addition, the three best-selling products of roche Rituxan (Rituxan), bevacizumab (Avastin) and by bead sheet resistance (Herceptin) would be ranked 2017 of the world's best-selling drug list of Top 10 3, 4, 6, it will face similar biological medicine in the next few years.
Teva edging out AZ into the top 10 list of new faces
However, although the United States pharmaceutical industry will face at the policy level changes (such as change the FDA commissioner, just through the 21st century to cure act to accelerate drug development, the new government is likely to price control measures), ranking pattern of global drug companies are not in a short period of time, great changes have taken place unless there is a super mergers and acquisitions.
Pfizer's dominance is still shake, expects its 2017 prescription and OTC sales of up to $49.9 billion, this part of the thanks to the hesion (Hospira) of mergers and acquisitions. Novartis with roche will go hand in hand, respectively 2, 3, 2017 prescription and OTC sales were $42.5 billion.
Sanofi, Merck, Johnson and Johnson and GlaxoSmithKline (GlaxoSmithKline) global drug companies in the Top 10 in the middle position, forecast revenue in the range of $2017 in 31.2 billion (GSK) ~ (sanofi) $39.9 billion. AbbVie (AbbVie), gilead with generic drugs giants Teva (Teva) divvied up the list of the rest of the seats, its 2017 revenue is expected to more than $200. It is worth mentioning, teva is the new face of the list in last year's report, in the position of the enterprise is AstraZeneca (AstraZeneca). |
